Bavarian Nordic A/s

Janssen Vaccines & Prevention B.v.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Robin Steigerwald

Ulrike Dirmeier

Ariane Volkmann

Paul Chaplin

Cédric Cheminay

Benoit Christophe Stephan Callendret

Lucy A Ward

Maria Grazia Pau

Markus Kalla

Jürgen Hausmann

Kay Brinkmann

Hubertus Hochrein

Henning Lauterbach

Eva Felder

Christine Meisinger-Henschel

Josef Weigl

Macaya Julie Douoguih

Ramon Roozendaal

Jutta Sytske Hartkoorn-Pasma

Cedric Cheminay

Jurgen Hausmann

Christine Meinsinger-Henschel

The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

Methods and compositions for inducing protective immunity against filovirus infection

The present invention relates to recombinant modified vaccinia virus Ankara (MVA) and to methods of using the same. In particular, the invention relates to recombinant MVA comprising a nucleotide sequence encoding for a structural protein of an equine encephalitis virus (EEV) excluding encoding for a capsid protein of the EEV, a composition in particular a pharmaceutical composition, a vaccine or kit comprising the recombinant MVA, uses and methods thereof e.g., suitable for treating and/or preventing a western, Venezuelan, and/or eastern equine encephalitis virus caused disease.

Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA and FPV vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a Marburg virus (MARV) or Ebola virus glycoprotein. Specifically, the invention relates to recombinant MVA comprising Ebola virus glycoprotein and virion protein 40. The invention also relates to products, methods and uses thereof as well as prime/boost regimens of MVA and genetically engineered (recombinant) FPV, e.g., suitable to induce a protective immune response in a subject.

Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens

The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.

Stable recombinant MVA vectors comprising modified RSV genes with reduced intramolecular recombinatorial activity

The present invention relates to modified poxviral vectors and to methods of making and using the same. In particular, the invention relates to recombinant modified vaccinia virus Ankara-based (MVA-based) vaccine against FMDV infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) MVA vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a FMDV protein. The invention also relates to products, methods and uses thereof, e.g., suitable to induce a protective immune response in a subject.

Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine

The invention encompasses recombinant poxviruses, preferably modified Vaccinia Ankara (MVA) viruses, comprising a Pr13.5 promoter operably linked to a nucleotide sequence encoding an antigen and uses thereof. The invention is drawn to compositions and methods for the induction of strong CD8 T cell and antibody responses to a specific antigen(s) by administering one or more immunizations of the recombinant MVA to a mammal, preferably a human.

PR13.5 promoter for robust T-cell and antibody responses

Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.

Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.

Methods and compositions for inducing protective immunity against a marburg virus infection

Recombinant modified vaccinia virus Ankara (MVA) equine encephalitis virus vaccine

The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to MVA can vastly increase the B cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens. Thus, the addition of an oil and water emulsion to MVA can increase the protective immune response. The invention encompasses administering a dose of an MVA in an oil and water emulsion to an animal, especially a human.

Use of oil and water emulsions for increasing B cell responses with modified Vaccinia Ankara virus

Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use

Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an MVA vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response. The compositions and methods can be used to provide a protective immunity against a disease, such as an infection of one or more subtypes of Ebola and Marburg filoviruses, in humans.

Growing community of inventors

Munich, Germany

Robin Steigerwald